<DOC>
	<DOCNO>NCT02092467</DOCNO>
	<brief_summary>This post-marketing study design compare safety tofacitinib versus TNF inhibitor respect major cardiovascular adverse event malignancy , exclude non-melanoma skin cancer give subject rheumatoid arthritis . Other safety event , include non-melanoma skin cancer , hepatic event , infection , efficacy parameter collect evaluated study .</brief_summary>
	<brief_title>Safety Study Of Tofacitinib Versus Tumor Necrosis Factor ( TNF ) Inhibitor In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate severe rheumatoid arthritis Taking methotrexate without adequate control symptom Have least one cardiovascular risk factor ( eg , current smoker , high blood pressure , high cholesterol level , diabetes mellitus , history heart attack , family history coronary heart disease , extraarticular RA disease ) Current recent infection Clinically significant laboratory abnormality Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Post-marketing</keyword>
	<keyword>Phase 4</keyword>
	<keyword>Open-label</keyword>
	<keyword>Safety Surveillance</keyword>
	<keyword>CP690550</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>oral treatment</keyword>
</DOC>